 |
196 Products |  |
52 Diseases | | 196 Products |
|
3529 Trials |  |
15381 News |  |
| «12...3031323334353637383940...208209» |
- ||||| SHR-1501 / Jiangsu Hengrui Pharma
New P1/2 trial: Phase I/II Clinical Study of SHR-1501 Combined With Adbelizumab in Patients With Malignant Tumors (clinicaltrials.gov) - Jul 18, 2025
P1/2, N=203, Not yet recruiting, Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd.
- ||||| Hengqu (hetrombopag) / Jiangsu Hengrui Pharma
Trial completion: Hetrombopag for Pediatric Patients With Chronic Immune Thrombocytopenia (clinicaltrials.gov) - Jul 18, 2025
P3, N=100, Completed, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Active, not recruiting --> Completed
- |||| HRS-4642 / Jiangsu Hengrui Pharma
Enrollment open, Enrollment change: HRS-4642 in Combination With AG for Neoadjuvant and Adjuvant Treatment of Pancreatic Cancer (clinicaltrials.gov) - Jul 17, 2025
P2, N=60, Recruiting, Sponsor: Ruijin Hospital
Active, not recruiting --> Completed N=20 --> 60 | Not yet recruiting --> Recruiting
- | New P2 trial: Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II Trial (clinicaltrials.gov) - Jul 17, 2025
P2, N=208, Recruiting, Sponsor: Ming-Yuan Chen
- |||| trastuzumab rezetecan (SHR-A1811) / Jiangsu Hengrui Pharma
Enrollment closed: SHR-A1811-309: Injection of SHR-A1811 Versus Physician Choiced Treatment in Patients With Advanced Colorectal Cancer Who Had Failed to Respond to Oxaliplatin, 5-fu, and Irinotecan (clinicaltrials.gov) - Jul 17, 2025
P3, N=130, Active, not recruiting, Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.
N=20 --> 60 | Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- |||| CS1002 (ipilimumab biosimilar) / CStone Pharma
New P2 trial: A Phase II Study of SHR-8068 Injection in Combination With Anti-tumor Therapies in Colorectal Cancer (clinicaltrials.gov) - Jul 17, 2025
P2, N=200, Not yet recruiting, Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- || HRS-5965 / Jiangsu Hengrui Pharma
Enrollment closed: Investigation of Drug-drug Interaction of HRS-5965 With Clopidogrel and Clarithromycin in Healthy Subjects (clinicaltrials.gov) - Jul 17, 2025
P1, N=36, Active, not recruiting, Sponsor: Chengdu Suncadia Medicine Co., Ltd.
Recruiting --> Active, not recruiting Not yet recruiting --> Active, not recruiting
- | AnDaJing (vunakizumab) / Jiangsu Hengrui Pharma, AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
New P2 trial: A Study on the First-line Treatment of Small Cell Lung Cancer With Adebrelimab and Vunakizumab and Chemotherapy (clinicaltrials.gov) - Jul 16, 2025
P2, N=28, Not yet recruiting, Sponsor: Fujian Cancer Hospital
- | New trial: Adjuvant Immunotherapy for Esophageal Squamous Cell Carcinoma (clinicaltrials.gov) - Jul 16, 2025
P=N/A, N=98, Not yet recruiting, Sponsor: Sichuan University
- || SHR-1918 / Jiangsu Hengrui Pharma
Clinical, Journal: SHR-1918, A Monoclonal Antibody Against Angiopoietin-Like 3, in Healthy Subjects: A Randomized, Double-Blind, Placebo-Controlled Study. (Pubmed Central) - Jul 16, 2025
P1
Not yet recruiting --> Active, not recruiting SHR-1918 was well tolerated and showed promising efficacy in lipid reduction among healthy subjects.
- | AiTan (rivoceranib) / HLB Bio Group, Avastin (bevacizumab) / Roche
Journal: JAK3/STAT5A-dependent IL-8 regulation drives ESCC angiogenesis and is suppressed by dihydroartemisinin. (Pubmed Central) - Jul 16, 2025
Besides, DHA inhibited ESCC angiogenesis through JAK3/STAT5A/IL-8 signaling in vivo and in vitro, and JAK3 blockade alleviated its effect. In conclusion, these findings demonstrate a critical role of the JAK3/STAT5A/IL-8 pathway in regulating ESCC angiogenesis, and DHA is an effective drug for targeting JAK3 against ESCC angiogenesis, providing a research basis and a new strategy for anti-ESCC angiogenesis therapy.
- ||| AiSuDa (ivarmacitinib) / Jiangsu Hengrui Pharma, Arcutis
Clinical, P3 data, Journal: Ivarmacitinib for Moderate to Severe Atopic Dermatitis in Adults and Adolescents: A Phase 3 Randomized Clinical Trial. (Pubmed Central) - Jul 16, 2025
P3
These results support the potential of ivarmacitinib as a new therapeutic option. ClinicalTrials.gov Identifier: NCT04875169.
- | Journal: Long-term survival in advanced pulmonary large-cell neuroendocrine carcinoma after multi-line immunochemotherapy and anti-angiogenic therapy: a case report. (Pubmed Central) - Jul 15, 2025
Third-line treatment maintained atezolizumab and introduced the anti-angiogenic agent anlotinib and chemotherapeutic agent pemetrexed, resulting in a PFS3 of 6 months...This case illustrates the potential for long-term survival in advanced PLCNEC through intensive, multi-line combination therapies. The favorable outcome observed in this patient supports further investigation of such combination strategies in clinical studies.
- | Retrospective data, Journal: Efficacy and Safety of Hepatic Artery Infusion Chemotherapy Combined with Donafenib and Camrelizumab in the Treatment of Patients with Unresectable Hepatocellular Carcinoma: A Retrospective, Single-Arm Study. (Pubmed Central) - Jul 15, 2025
Grade 3 or higher TRAEs were observed in 61.2% of patients. For patients with uHCC, the combination therapy of FOLFOX-HAIC with donafenib and camrelizumab demonstrates favorable efficacy and manageable adverse events.
- | New P2 trial: RC48 Plus Bevacizumab or Pyrotinib in HER2-Positive Metastatic Breast Cancer After T-DXd Failure: A Phase II Study (clinicaltrials.gov) - Jul 15, 2025
P2, N=74, Recruiting, Sponsor: The First Affiliated Hospital with Nanjing Medical University
- || Jardiance (empagliflozin) / Eli Lilly, Boehringer Ingelheim, Ruiqin (henagliflozin) / Jiangsu Hengrui Pharma, sorafenib / Generic mfg.
PK/PD data, Preclinical, Journal: In vivo assessment of pharmacokinetic interactions of empagliflozin and henagliflozin with sorafenib: an animal-based study. (Pubmed Central) - Jul 14, 2025
Empagliflozin and henagliflozin inhibited Oatp1b2 expression in the liver and P-gp expression in the liver and intestines. These pharmacokinetic interactions provide valuable insights for future studies on optimizing the dosing regimens of sorafenib in combination with empagliflozin or henagliflozin, potentially reducing toxicity risks and improving the safety of coadministration in clinical settings.
- || oxaliplatin / Generic mfg., Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka, AiRuiKa (camrelizumab) / HLB Bio Group
P2 data, Journal: Camrelizumab plus SOX chemotherapy as adjuvant therapy for pathological stage III gastric or gastroesophageal junction adenocarcinoma: a prospective, multicenter, single-arm, phase II trial. (Pubmed Central) - Jul 14, 2025
P2
However, careful patient selection is necessary to identify patients most likely to benefit from combination therapy. ClinicalTrials.gov registry: NCT04515615; Date of registration: August 14, 2020; Weblink: https://clinicaltrials.gov/study/NCT04515615.
- || recaticimab (SHR-1209) / Jiangsu Hengrui Pharma, AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
New P2 trial: HP-BTC-002: A Trial of Recaticimab and Adebrelimab in Combination With Chemotherapy in Patients With Unresectable BTC (clinicaltrials.gov) - Jul 14, 2025
P2, N=39, Not yet recruiting, Sponsor: Sun Yat-sen University
- || risvutatug rezetecan (GSK5764227) / GSK
New P1 trial: Phase 1 Study of HS-20093 Combinations in Patients With Extensive Stage Small Cell Lung Cancer (clinicaltrials.gov) - Jul 14, 2025
P1, N=50, Not yet recruiting, Sponsor: Shanghai Hansoh Biomedical Co., Ltd
- | Tevimbra (tislelizumab-jsgr) / BeOne Medicines, AiRuiKa (camrelizumab) / HLB Bio Group
Trial completion date, Trial primary completion date, Checkpoint inhibition: Efficacy and Safety of Super-hyperfractionation Pulse Radiotherapy Combined With ICIs for Advanced NSCLC (clinicaltrials.gov) - Jul 14, 2025
P=N/A, N=40, Recruiting, Sponsor: Xinqiao Hospital of Chongqing
ClinicalTrials.gov registry: NCT04515615; Date of registration: August 14, 2020; Weblink: https://clinicaltrials.gov/study/NCT04515615. Trial completion date: Mar 2025 --> Mar 2026 | Trial primary completion date: Mar 2025 --> Mar 2026
- tegileridine (SHR8554) / Jiangsu Hengrui Pharma
Tegileridine for Postoperative Pain Management in Abdominal Surgery: A Randomized, Double-Blind, Phase 3 Clinical Trial (221D, Meeting Level) - Jul 12, 2025 - Abstract #ASA2025ASA_4346;
Trial completion date: Mar 2025 --> Mar 2026 | Trial primary completion date: Mar 2025 --> Mar 2026 Abstract is embargoed at this time.
- |||||||||| ribupatide injection (HRS9531 injection) / Kailera Therapeutics
New P3 trial: Efficacy and Safety of HRS9531 in Participants With Type 2 Diabetes Treated With Basal Insulin (clinicaltrials.gov) - Jul 11, 2025
P3, N=300, Not yet recruiting, Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd.
- | AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma, HRS-2189 / Jiangsu Hengrui Pharma
New P2 trial: An Explorative Study of HRS-2189 Combined With Adebrelimab and BP102 for Metastatic Colorectal Cancer (clinicaltrials.gov) - Jul 11, 2025
P2, N=20, Not yet recruiting, Sponsor: Fudan University
- | Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, AiRuiKa (camrelizumab) / HLB Bio Group
New P2 trial: Union-mRC: Short Course Radiotherapy Followed by CAPOX and Carrilizumab and Bevacizumab or Cetuximab for the Initial Treatment of Unresectable Metastatic Rectal Cancer (clinicaltrials.gov) - Jul 11, 2025
P2, N=80, Not yet recruiting, Sponsor: Wuhan Union Hospital, China
- ||| NovaTears (perfluorohexyloctane) / Novaliq, Bausch Health, AFT Pharma
Enrollment open: A Study to Evaluate Concomitant Perfluorohexyloctane Use With Contact Lens Wear (clinicaltrials.gov) - Jul 11, 2025
P4, N=100, Recruiting, Sponsor: Bausch & Lomb Incorporated
Abstract is embargoed at this time. Not yet recruiting --> Recruiting
- || SHR-1707 / Jiangsu Hengrui Pharma
Trial completion, Enrollment change, Trial completion date, Trial primary completion date: A Trial of SHR-1707 Infusion in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild Alzheimer's Disease (clinicaltrials.gov) - Jul 11, 2025
P1, N=2, Completed, Sponsor: Atridia Pty Ltd.
Not yet recruiting --> Recruiting Active, not recruiting --> Completed | N=12 --> 2 | Trial completion date: Nov 2025 --> Jul 2025 | Trial primary completion date: Nov 2025 --> Jul 2025
- || Retrospective data, Review, Journal: Updated Network Meta-Analysis of First-Line Systemic Treatments for Advanced HCC: Consistent Role of TACE. (Pubmed Central) - Jul 11, 2025
For advanced HCC, our first-line analysis consistently scored TACE + lenvatinib the best for survival outcomes, followed by various immunotherapy-based combinations. However, the superior efficacy of TACE + lenvatinib should be interpreted with consideration of its derivation from a region with high hepatitis B virus prevalence.
- ||| Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
Journal, Adverse events, Tumor mutational burden, PARP Biomarker, PD(L)-1 Biomarker, IO biomarker: Prolonged Progression-Free Survival in a Patient with Highly Pretreated Recurrent Ovarian Cancer after Developing Multisystem Immune-Related Adverse Events: A Case Report and Literature Review. (Pubmed Central) - Jul 11, 2025
From May 2022, the patient was switched to maintenance therapy with tislelizumab plus olaparib...We report a case involving a patient with highly pretreated recurrent ovarian cancer who exhibited prolonged PFS after developing three irAEs. The distinctly prolonged PFS observed, along with the reviewed literature, suggests that irAEs may be correlated with improved survival in ovarian cancer.
- ||||||| ribupatide injection (HRS9531 injection) / Kailera Therapeutics
Trial completion: To Compare the Efficacy and Safety of HRS9531 and Placebo in Subjects With Overweight or Obese (clinicaltrials.gov) - Jul 11, 2025
P3, N=567, Completed, Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd.
The distinctly prolonged PFS observed, along with the reviewed literature, suggests that irAEs may be correlated with improved survival in ovarian cancer. Recruiting --> Completed
- | AiTan (rivoceranib) / HLB Bio Group
Journal, PARP Biomarker: Proteomics profiling reveals the potential targets of Apatinib inhibiting the proliferation of glioma U251 (Pubmed Central) - Jul 10, 2025
Molecular docking studies further substantiated our findings, showing strong binding affinity between Apatinib and both DKK1 and PARP14. Collectively, our results suggest that these proteins represent promising therapeutic targets for glioma treatment.
- | Kaitanni (cadonilimab) / Akesobio
Enrollment open: Neoadjuvant Cadonilimab Combined With Perioperative Oxaliplatin Plus S1 for Diffuse or Mixed Type of Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma (clinicaltrials.gov) - Jul 10, 2025
P3, N=668, Recruiting, Sponsor: Zuoyi Jiao
Collectively, our results suggest that these proteins represent promising therapeutic targets for glioma treatment. Not yet recruiting --> Recruiting
- | SHR-1819 / Jiangsu Hengrui Pharma
Trial completion date, Trial primary completion date: SHR-1819-204: A Phase Ib/II Study to Investigate the Safety of SHR-1819 in Children and Adolescents With Moderate-to-severe Atopic Dermatitis (clinicaltrials.gov) - Jul 10, 2025
P1/2, N=50, Recruiting, Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd
Not yet recruiting --> Recruiting Trial completion date: Aug 2025 --> Dec 2025 | Trial primary completion date: Jun 2025 --> Sep 2025
- | AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
Enrollment closed, Trial completion date, Trial primary completion date: Camrelizumab in Combination With Apatinib in Patients With Radioactive Iodine-refractory Differentiated Thyroid Cancer (clinicaltrials.gov) - Jul 10, 2025
P2, N=20, Active, not recruiting, Sponsor: Peking Union Medical College Hospital
Trial completion date: Aug 2025 --> Dec 2025 | Trial primary completion date: Jun 2025 --> Sep 2025 Recruiting --> Active, not recruiting | Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2023 --> Dec 2025
- | AnDaJing (vunakizumab) / Jiangsu Hengrui Pharma
Enrollment open, Trial completion date, Trial primary completion date: Vunakizumab for the Treatment of Mild to Moderate Systemic Lupus Erythematosus (clinicaltrials.gov) - Jul 10, 2025
P1, N=20, Recruiting, Sponsor: Chinese SLE Treatment And Research Group
Recruiting --> Active, not recruiting | Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2023 --> Dec 2025 Not yet recruiting --> Recruiting | Trial completion date: Apr 2027 --> Dec 2027 | Trial primary completion date: Oct 2025 --> Nov 2026
- | Ruiqin (henagliflozin) / Jiangsu Hengrui Pharma
Trial completion, Enrollment change, Trial completion date: Effects of Henagliflozin on the Brain Function in T2DM Patients With Mild Cognitive Impairment: a Randomized, Parallel Controlled Clinical Trial (clinicaltrials.gov) - Jul 10, 2025
P=N/A, N=24, Completed, Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Not yet recruiting --> Recruiting | Trial completion date: Apr 2027 --> Dec 2027 | Trial primary completion date: Oct 2025 --> Nov 2026 Recruiting --> Completed | N=60 --> 24 | Trial completion date: Jun 2026 --> Jun 2025
- |||| SHR-A2102 / Jiangsu Hengrui Pharma, AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
New P1/2 trial: A Trial of SHR-A2102 With Adebrelimab With or Without Other Anti-tumor Therapies in Recurrent/MetastaticHead and Neck Squamous Cell Carcinoma Cancer (clinicaltrials.gov) - Jul 10, 2025
P1/2, N=96, Not yet recruiting, Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- AiRuiKa (camrelizumab) / HLB Bio Group
EFFICACY AND SAFETY OF CAMRELIZUMAB IN ESOPHAGEAL SQUAMOUS CELL CARCINOMA: A SYSTEMATIC REVIEW AND META-ANALYSIS (Science Lounge) - Jul 9, 2025 - Abstract #UEGW2025UEGW_2502;
The safety profile is acceptable with controllable adverse effects. These findings support the potential therapeutic value of camrelizumab as a significant treatment strategy in multimodal treatment of esophageal squamous cell carcinoma and the need for further research to optimize its clinical use.
- | NovaTears (perfluorohexyloctane) / Novaliq, Bausch Health, AFT Pharma
Journal: Factors Associated With Perfluorohexyloctane Treatment Response in Dry Eye Disease Associated With Meibomian Gland Dysfunction. (Pubmed Central) - Jul 9, 2025
P3
Baseline tCFS score and ametropia are critical factors associated with SHR8058 treatment response. Patients with a baseline tCFS score ?6 and those with ametropia are more likely to achieve greater overall improvements of corneal surface condition and dry eye symptoms.
- | AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
New P2 trial: Single-Arm Exploratory Study of PD-L1 Antibody Plus Neoadjuvant Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov) - Jul 9, 2025
P2, N=69, Recruiting, Sponsor: Xiuping Ding
- || Review, Journal: A momentous progress update: epidermal growth factor receptor inhibitors as viable agents for combating cancer. (Pubmed Central) - Jul 9, 2025
Preclinical, clinical, structure-activity relationships (SAR) with mechanism-based and in silico research, and other relevant data are compiled to offer directions for the scientific discovery of novel EGFR inhibitors with conceivable uses in therapy. The research trajectory of this entire field will provide incessant opportunities for the discovery of novel drug molecules with improved efficacy and selectivity.
- | AiRuiKa (camrelizumab) / HLB Bio Group
New P2 trial, pMMR: Involved-field Radiotherapy-TNT Combined With PD-1 Inhibitor for pMMR Locally Advanced Rectal Cancer (Neo-Field I) (clinicaltrials.gov) - Jul 8, 2025
P2, N=162, Recruiting, Sponsor: Hebei Medical University Fourth Hospital
- | AiRuiKa (camrelizumab) / HLB Bio Group
New trial: Efficacy of Argon-Helium Cryoablation Plus PD-1 Inhibitors in NSCLC (clinicaltrials.gov) - Jul 8, 2025
P=N/A, N=60, Completed, Sponsor: The First Hospital of Hebei Medical University
- || Clinical, Retrospective data, Journal: The safety and effectiveness of sintilimab versus camrelizumab, both plus targeted drugs, in advanced hepatocellular carcinoma. (Pubmed Central) - Jul 8, 2025
Sintilimab and camrelizumab, both plus targeted agents, have equal clinical effectiveness and incidences of AEs. The effectiveness of sintilimab-lenvatinib and camrelizumab-apatinib are similar in first-line treatment of advanced HCC, despite a slight superiority in sintilimab-lenvatinib is observed.
- |||| NovaTears (perfluorohexyloctane) / Novaliq, Bausch Health, AFT Pharma
New P4 trial: A Study to Evaluate Concomitant Perfluorohexyloctane Use With Contact Lens Wear (clinicaltrials.gov) - Jul 8, 2025
P4, N=100, Not yet recruiting, Sponsor: Bausch & Lomb Incorporated
- | Keytruda (pembrolizumab) / Merck (MSD), Opdivo (nivolumab) / Ono Pharma, BMS, AiRuiKa (camrelizumab) / HLB Bio Group
New trial: Patient Derived Organoids (PDOs) to Observe the Clinical Consistency of Personalized Neoadjuvant Therapy for Resectable Esophageal Squamous Cell Carcinoma (clinicaltrials.gov) - Jul 8, 2025
P=N/A, N=30, Recruiting, Sponsor: Shanghai Zhongshan Hospital
- |||| Tyvyt (sintilimab) / Innovent Biologics, Eli Lilly, Irene (pyrotinib) / Jiangsu Hengrui Pharma
New P2 trial: CCGLC-018: A Prospective, Open-label, Exploratory Basket Trial to Evaluate the Efficacy and Safety of Sintilimab Combined With Pyrotinib (clinicaltrials.gov) - Jul 8, 2025
P2, N=80, Not yet recruiting, Sponsor: Tongji Hospital
- | Ruiqin (henagliflozin) / Jiangsu Hengrui Pharma
Enrollment open: An Observational Study on the Safety and Efficacy of Henagliflozin in Chinese Patients With Type 2 Diabetes (clinicaltrials.gov) - Jul 7, 2025
P=N/A, N=10000, Recruiting, Sponsor: Second Affiliated Hospital of Guangxi Medical University
The effectiveness of sintilimab-lenvatinib and camrelizumab-apatinib are similar in first-line treatment of advanced HCC, despite a slight superiority in sintilimab-lenvatinib is observed. Not yet recruiting --> Recruiting
- AiRuiKa (camrelizumab) / HLB Bio Group
Induction-Concurrent Chemoradiotherapy with or without Camrelizumab for Postoperative Residual High-Grade Gliomas: An Open, Randomized, Phase II Clinical Study (Room 307/308) - Jul 7, 2025 - Abstract #ASTRO2025ASTRO_2690;
- AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
Efficacy and Safety of Camrelizumab and Apatinib in Combination with IMRT in Unresectable Hepatocellular Carcinoma: A Non-Randomised Phase 2 Study (Room 22/23) - Jul 7, 2025 - Abstract #ASTRO2025ASTRO_2133;
- || ribupatide injection (HRS9531 injection) / Kailera Therapeutics
Trial completion: Mass Balance Study of [14C]HRS9531 in Healthy Male Subjects (clinicaltrials.gov) - Jul 7, 2025
P1, N=7, Completed, Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd.
Not yet recruiting --> Recruiting Not yet recruiting --> Completed